Pricing Log in Create free account
Saturday 7 November 2026 Export SGMOQ’s income statement to Excel — free account

Sangamo Therapeutics, Inc.

SGMOQ Healthcare Biotechnology

Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.

Revenue
−77.6%
EPS
+42.9%
Free cash flow
+26.2%

Quarter to March 2026, against a year earlier

0.11 0.00 0.00%
Market cap
$41.9M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
3/9
Altman Z
−43.35
Beneish M
−5.11
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.11
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — 2 — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 41.89
Revenue ttm 34.56
Net income ttm (123.33)
Free cash flow ttm (90.46)
Net debt Q (27.59)
Valuation
P/E 0.00
Forward P/E (0.96) (negative: loss-making)
Price / sales 1.24
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.70 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −77.60% (below 0%: shrinking)
Operating income growth Q −7.82% (below 0%: shrinking)
EPS, this year +56.82% (at or above 15%: strong)
EPS, next year A +71.05% (at or above 15%: strong)
Revenue, next year A −74.97% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +73.79% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 5.6×; over the ten years it ranged from −0.1× in 2023 to 45.2× in 2018.
P/S against its own 10 years 10.63%
10-year low 10-year high
EV/Sales against its own 10 years 9.26%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 81 42 21 28
Receivables 1 1 0 1
Inventory — — — —
Other 3 4 10 5
94 52 36 37
2023 2024 2025 Q'26
Payables 15 15 14 19
ST’ Debt — — — —
Other — — — —
48 46 42 53

Compound Annual Growth %

10y 5y 3y
Sales 0.00% (19.66%) (29.17%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

EPS $

Mar Jun Sep Dec Year
’26 (0.08) — — — —
’25 (0.14) (0.08) (0.11) (0.11) (0.44)
’24 (0.27) (0.18) 0.04 (0.11) (0.49)
’23 0.12 (0.66) (0.59) (0.34) (1.48)
’22 (0.30) (0.29) (0.34) (0.32) (1.25)
’21 (0.32) (0.33) (0.33) (0.26) (1.23)
’20 (0.37) (0.26) (0.01) (0.29) (0.90)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 — — — —
’25 6 18 1 14 40
’24 0 0 49 8 58
’23 158 7 9 2 176
’22 28 29 26 27 111
’21 26 28 29 28 111
’20 13 22 58 26 118
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) — — — —
’25 (26) (18) (28) (24) (97)
’24 (49) (27) 12 (3) (67)
’23 (66) (61) (47) (51) (225)
’22 (59) (54) (54) (57) (224)
’21 (69) (53) (59) (53) (233)
’20 (19) 160 33 (4) 170
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) — — — —
’25 (26) (18) (29) (24) (97)
’24 (49) (27) 12 (4) (67)
’23 (76) (66) (50) (53) (246)
’22 (62) (59) (58) (65) (244)
’21 (76) (60) (65) (56) (257)
’20 (23) 157 29 (8) 155
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Mar ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 19 37 84 102 118 111 111 176 58 40 35 +8.2% 10 71 141 +52.7%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (72) (55) (69) (95) (121) (178) (192) (263) (98) (123) (124) +6.2%
EBT margin, % (369.65) (149.23) (81.57) (93.16) (102.19) (160.79) (172.37) (149.18) (169.74) (312.25) (358.88) +57.4 pt
Net income (72) (55) (69) (95) (121) (178) (192) (258) (98) (123) (123) +6.2%
Per share, $
Per share, $ Revenue 0.27 0.47 0.87 0.91 0.88 0.77 0.72 1.01 0.29 0.14 0.09 (7.1%)
Earnings (1.02) (0.70) (0.70) (0.85) (0.90) (1.23) (1.25) (1.48) (0.49) (0.44) (0.38) (8.9%)
Cash flow (0.93) 0.14 0.38 (1.29) 1.26 (1.61) (1.45) (1.29) (0.33) (0.35) (0.23) (10.4%)
Capex (0.01) (0.05) (0.44) (0.18) (0.11) (0.16) (0.13) (0.12) 0.00 0.00 0.00 (30.4%)
Free cash flow (0.94) 0.10 (0.07) (1.47) 1.15 (1.77) (1.58) (1.41) (0.33) (0.35) (0.23) (10.5%)
Book value 1.93 2.41 3.79 3.86 3.70 2.60 1.91 0.48 0.11 (0.05) (0.05) n/m
Shares, m 71 78 97 112 134 145 154 174 202 280 308 +16.6%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 11.28 37.48 13.18 9.16 17.76 9.79 4.35 0.55 3.56 2.98 1.24 11.0
P/B 1.61 7.29 3.03 2.17 4.22 2.89 1.64 1.18 9.04 0.00 0.00 3.3
EV/Sales 4.13 31.50 8.77 5.89 12.56 6.64 2.11 0.25 3.31 3.15 1.24 7.8
EV/FCF (1.20) 155.06 (113.65) (3.66) 9.57 (2.87) (0.96) (0.18) (2.63) (1.27) (0.47) 3.8
Cash, $m
Cash, $m Operating cash flow (66) 11 37 (144) 170 (233) (224) (225) (67) (97) (90) +4.4%
Capex (1) (4) (43) (21) (15) (23) (20) (21) 0 0 0 (19.7%)
Free cash flow (67) 7 (7) (165) 155 (257) (244) (246) (67) (97) (90) +4.3%
Balance, $m
Balance, $m Working capital 136 204 332 336 516 271 189 47 6 (7) (16) n/m
Net debt (139) (219) (372) (362) (641) (377) (278) (81) (42) (21) (28) (18.9%)
Shareholders’ equity 136 188 367 433 497 375 295 83 23 (14) (19) n/m
Returns, %
Returns, % ROA (38.20) (24.55) (15.58) (15.50) (15.35) (21.47) (29.94) (70.85) (73.38) (152.35) (168.79) (114.2) pt
ROIC 0.00 0.00 0.00 (93.56) 0.00 0.00 (726.08) (9,085.05) 0.00 0.00 0.00 0.0 pt
ROE (43.61) (33.67) (24.62) (23.80) (26.02) (40.86) (57.37) (136.47) (185.39) (2,891.84) 1,755.72 (2,848.2) pt
People
People Employees 131 182 302 354 413 431 478 405 183 142 — +0.9%
Revenue/emp, $m 0.15 0.20 0.28 0.29 0.29 0.26 0.23 0.44 0.32 0.28 — +7.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Sangamo Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BMEA Biomea Fusion, Inc. $42.6M — (loss-making) — — n/m +47.80% (above 0%: growing) 0.00% 0.00% Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR $42.4M — (loss-making) — — 0.00% −84.83% (below 0%: shrinking) 0.00% — Compare
GANX Gain Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +27.78% (above 0%: growing) n/m +8.22% (above 0%: growing) 0.00% 0.00% Compare
SER Serina Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%)
LONA LeonaBio, Inc. $40.9M — (loss-making) — — n/m −142.29% (below 0%: shrinking) 0.00% 0.00% Compare
ATNM Actinium Pharmaceuticals, Inc. $40.9M 3.9× 8.4× +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
HYPD Hyperion DeFi, Inc. $39.8M — (loss-making) 0.5× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63% Compare
DWTX Dogwood Therapeutics, Inc $39.8M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
Median of peers $41.4M — — +2,416.67% — +1.66% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 2.46m 3.97m 13.60
2023 2.39m (340.20k) 7.24
2022 4.81m 967.86k 41.87

Ownership

Directors and executive officers, together 4.10%
Wasatch Advisors, Inc.505 Wakara Way, 6.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Sangamo Therapeutics, Inc. (SGMOQ) Latest News

13 Oct

Impact 4 · · GlobeNewswire

13 Aug

Impact 4 · · biopharmadive.com

12 Aug

Impact 4 ·
Impact 4 ·

24 Jun

Impact 5 · · biopharmadive.com

23 Jun

Impact 4 · · GlobeNewswire

8 Jun

Impact 4 · · GlobeNewswire

15 May

Impact 3 · · Moby
Impact 3 · · GuruFocus.com

14 May

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

30 Apr

Impact 3 · · GlobeNewswire

29 Apr

Impact 4 · · InvestorsHub
Impact 4 · · GlobeNewswire

31 Mar

Impact 4 · · Moby

30 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat

9 Mar

Impact 4 · · GlobeNewswire

4 Feb

Impact 4 · · Simply Wall St.

3 Feb

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

23 Jan

Impact 4 · · Simply Wall St.

12 Jan

Impact 3 · · Insider Monkey

18 Dec

Impact 4 · · GlobeNewswire

12 Dec

Impact 4 · · Simply Wall St.

3 Dec

Impact 4 · · PR Newswire

2 Dec

Impact 4 · · GlobeNewswireMotley FoolMT NewswiresSimply Wall St.MT NewswiresSimply Wall St.Simply Wall St.MT Newswires
Impact 3 · · Associated Press Finance

28 Nov

Impact 4 · · Simply Wall St.Simply Wall St.MT NewswiresSimply Wall St.Motley FoolSimply Wall St.Simply Wall St.Simply Wall St.
stockrow.com/SGMOQ · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com